原发性胆汁性肝硬化诊治进展

宁惠明; 欧强

doi:10.3969/j.issn.1001-5256.2016.04.045

原发性胆汁性肝硬化诊治进展

DOI: 10.3969/j.issn.1001-5256.2016.04.045

宁惠明,
欧强

上海市第八人民医院感染科

详细信息

中图分类号: R575.22
计量
- 文章访问数: 2549
- HTML全文浏览量: 38
- PDF下载量: 526
- 被引次数: 0
出版历程
- 出版日期: 2016-04-20

Research advances in diagnosis and treatment of primary biliary cirrhosis

Department of Infectious Diseases, Shanghai Eighth People′s Hospital

摘要

摘要:
原发性胆汁性肝硬化(PBC)是一种以肝内小胆管进行性、非化脓性炎症为特征的慢性胆汁淤积性疾病,可导致肝纤维化及肝硬化。其病因和发病机制尚不清楚,疾病发生和进展认为是多因素的,大多是环境因素作用于遗传易感者。熊去氧胆酸是被认为是唯一有效的治疗药物,但完全应答率不是特别高。结合国内外文献,对PBC诊断和治疗作一简要综述。
- 肝硬化,胆汁性 /
- 诊断 /
- 治疗 /
- 综述
Abstract:
Primary biliary cirrhosis( PBC) is a chronic cholestatic liver disease,characterized by progressive non- pyogenic inflammation in the small intrahepatic bile ducts,and can cause hepatic fibrosis and liver cirrhosis. The etiology and pathogenesis of PBC remain unknown. The development and progression of PBC are caused by various factors,and the major factor is environmental factors acting on patients with genetic susceptibility. Ursodesoxycholic acid is thought to be the only effective drug,but the complete response rate remains low.This article reviews the diagnosis and treatment of PBC with reference to the literature in the world.
- liver cirrhosis,biliary /
- diagnosis /
- therapy /
- review

HTML全文

参考文献(33)

[1]CHEN QB,PENG AP,LI CC,et al.Suppressive effects of bezafibrate on proliferation and lytokine production by CD4+T tells from patients with primary biliary cirrhosis[J].Chin J Immunol,2014,30(10):1388-1392.(in Chinese)陈曲波,彭桉平,黎翠翠,等.苯扎贝特对原发性胆汁性肝硬化患者外周血CD4+T细胞的抑制作用研究[J].中国免疫学杂志,2014,30(10):1388-1392.

[2]KUMAGI T,HEATHCOTE EJ.Primary biliary cirrhosis[J].Nihon Naika Gakkai Zasshi,2008,3(5):1.

[3]ZHOU XY,TIAN YZ.The recent advances in the treatment of refractory primary biliary cirrhosis[J].Jilin J Tradit Chin Med,2014,34(11):1185-1188.(in Chinese)周新源,田耀州.难治性原发性胆汁性肝硬化治疗进展[J].吉林中医药,2014,34(11):1185-1188.

[4]CORPECHOT C,CHRETIEN Y,CHAZOUILLERES O,et al.Demographic,lifestyle,medical and familial factors associated with primary biliary cirrhosis[J].J Hepatol,2010,53(1):162-169.

[5]SILVEIRA MG,BRUNT EM,HEATHCOTE EJ,et al.American Association for the Study of Liver Diseases endpoints conference:design and endpoints for clinical trials in primary biliary cirrhosis[J].Hepatology,2010,52(1):349-359.

[6]POUPON R.Primary biliary cirrhosis:a 2010 update[J].J Hepatol,2010,52(5):745-758.

[7]LINDOR KD,GERSHWIN ME,POUPON R,et al.Primary biliary cirrhosis[J].Hepatology,2009,50(1):291-308.

[8]JIANG DQ,LU Y,SHEN G,et al.One case of serum AMA-M2 negative primary biliary cirrhosis[J/CD].Chin J Liver Dis:Electronic E-dition,2015,7(3):149-150.(in Chinese)蒋德强,路遥,申戈,等.血清AMA-M2阴性原发性胆汁性肝硬化1例[J/CD].中国肝脏病杂志:电子版,2015,7(3):149-150.

[9]MENDES F,LINDOR KD.Antimitochondrial antibody-negative primary biliary cirrhosis[J].Gastroenterol Clin North Am,2008,37(2):479-484.

[10]GUO YP,WANG CG,LIU X,et al.Evaluation of markers associated with primary biliary cirrhosis in a population of anti-mitochondrial antibody-M2-positive individuals[J].Chin J Hepatol,2014,22(10):735-738.(in Chinese)郭亚平,王春光,刘欣,等.抗线粒体抗体-M2阳性体检人群原发性胆汁性肝硬化相关指标的调查分析[J].中华肝脏病杂志,2014,22(10):735-738.

[11]MURATORI L,GRANITO A,MURATORI P,et al.Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis:diagnostic and prognostic value[J].Clin Liver Dis,2008,12(2):261-276.

[12]QIN X,YU J.Results analysis and clinical application of auto‐antibodies detection in primary biliary cirrhosis[J].Lab Med Clin,2015,1(4):484-485.(in Chinese)秦霞,余俊.原发性胆汁性肝硬化自身抗体检测结果分析及临床应用[J].检验医学与临床,2015,1(4):484-485.

[13]HU CJ,ZHANG FC,LI YZ,et al.Primary biliary cirrhosis:what do autoantibodies tell us?[J].World J Gastroenterol,2010,16(29):3616-3629.

[14]NAKAMURA M,KONDO H,MORI T,et al.Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis[J].Hepatology,2007,45(1):118-127.

[15]CZAJA AJ.The overlap syndromes of autoimmune hepatitis[J].Dig Dis Sci,2013,58(2):326-343.

[16]TALWALKAR JA.Current and emerging surrogate markers of hepatic fibrosis in primary biliary cirrhosis[J].Liver Int,2008,28(6):761-763.

[17]CORPECHOT C,El NAGGAR A,POUJOL-ROBERT A,et al.Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC[J].Hepatology,2006,43(5):1118-1124.

[18]FLOREANI A,FRANCESCHET I,CAZZAGON N,et al.Extrahepatic autoimmune conditions associated with primary biliary cirrhosis[J].Clin Rev Allergy Immunol,2015,48(2-3):192-197.

[19]TADA F,ABE M,NUNOI H,et al.Ulcerative colitis complicated with primary biliary cirrhosis[J].Intern Med,2011,50(20):2323-2327.

[20]KUMAGI T,GUINDI M,FISCHER SE,et al.Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis[J].Am J Gastroenterol,2010,105(10):2186-2194.

[21]AZEMOTO N,ABE M,MURATA Y,et al.Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis[J].J Gastroenterol,2009,44(6):630-634.

[22]AZEMOTO N,KUMAGI T,ABE M,et al.Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis[J].Hepatol Res,2011,41(4):310-317.

[23]CORPECHOT C,CARRAT F,BAHR A,et al.The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis[J].Gastroenterology,2005,128(2):297-303.

[24]WANG L,GUO GY,WANG JB,et al.A decline of LAMP-2predicts ursodeoxycholic acid response in primary biliary cirrhosis[J].Sci Rep,2015,20(5):9772.

[25]NGUYEN DL,JURAN BD,LAZARIDIS KN.Primary biliary cirrhosis[J].Best Pract Res Clin Gastroenterol,2010,24(5):647-654.

[26]POUPON R.Evidence-based treatment of primary biliary cirrhosis[J].Dig Dis,2014,32(5):626-630.

[27]ZHANG H,YANG J,ZHU R,et al.Combination therapy of ursodeoxycholic acid and budesonide for PBC-AIH overlap syndrome:a meta-analysis[J].Drug Des Devel Ther,2015,17(9):567-574.

[28]KAPLAN MM,BONDER A,RUTHAZER R,et al.Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid[J].Dig Dis Sci,2010,55(11):3207-3217.

[29]HOSONUMA K,SATO K,YAMAZAKII Y,et al.A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia[J].Am J Gastroenterol,2015,110(3):423-431.

[30]GRIGORIAN AY,MARDINI HE,CORPECHOT C,et al.Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis:a meta-analysis[J].Clin Res Hepatol Gastroenterol,2015,39:296-306.

[31]TSUDA M,MORITOKI Y,LIAN ZX,et al.Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid[J].Hepatology,2012,55(2):512-521.

[32]HIRSCHFIELD GM,MASON A,LUKETIC V,et al.Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J].Gastroenterology,2015,148(4):751-761.

[33]SCHREUDER TC,HUBSCHER SG,NEUBERGER J.Autoimmune liver diseases and recurrence after orthotopic liver transplantation:what have we learned so far?[J].Transpl Int,2009,22(2):144-152.

施引文献

资源附件(0)

访问统计